Evaluation of liposomal clodronate in experimental spontaneous autoimmune hemolytic anemia in dogs

Experimental Hematology

Volumn 34, Issue 10, 2006, Pages 1393-1402

  Mathes, Mark ^a   Jordan, Michael ^b   Dow, Steven ^a  

^a Department of Ecosystem Science and Sustainability   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; CLODRONIC ACID; LIPOSOMAL CLODRONATE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNE HEMOLYTIC ANEMIA; CELL KILLING; CLEARANCE; CONTROLLED STUDY; CYTOPENIA; DENDRITIC CELL; DISEASE SEVERITY; DOG; DRUG EFFICACY; DRUG INFUSION; DRUG SAFETY; DRUG TOLERABILITY; ERYTHROCYTE; EVALUATION; IN VITRO STUDY; IN VIVO STUDY; LOW DRUG DOSE; MACROPHAGE; NONHUMAN; OPSONIZATION; PILOT STUDY; PRIORITY JOURNAL; SPLEEN; SURVIVAL TIME; TREATMENT OUTCOME;

ANEMIA, HEMOLYTIC, AUTOIMMUNE; ANIMALS; BONE DENSITY CONSERVATION AGENTS; CLODRONIC ACID; DENDRITIC CELLS; DISEASE MODELS, ANIMAL; DOG DISEASES; DOGS; HUMANS; INFUSIONS, INTRAVENOUS; LIPOSOMES; MACROPHAGES; PHAGOCYTOSIS; RABBITS; SPLEEN; TREATMENT OUTCOME;

ANIMALIA; CANIS FAMILIARIS;

EID: 33748569522     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exphem.2006.05.014     Document Type: Article

References (44)

1. Rosse W.F., Hillmen P., and Schreiber A.D. Immune-mediated hemolytic anemia. Hematology (Am Soc Hematol Educ Program) (2004) 48-62
2. Axelson J.A., and LoBuglio A.F. Immune hemolytic anemia. Med Clin North Am 64 (1980) 597-606
3. Dhaliwal G., Cornett P.A., and Tierney Jr. L.M. Hemolytic anemia. Am Fam Physician 69 (2004) 2599-2606
4. Izui S. Autoimmune hemolytic anemia. Curr Opin Immunol 6 (1994) 926-930
5. Schreiber A.D. Systemic lupus erythematosus-hematological aspects. J Rheumatol 7 (1980) 395-397
6. Izui S., Berney T., Shibata T., Fulpius T., Fossati L., and Merino R. Molecular and cellular basis for pathogenicity of autoantibodies. Tohoku J Exp Med 173 (1994) 15-30
7. Fossati-Jimack L., Ioan-Facsinay A., Reininger L., et al. Markedly different pathogenicity of four immunoglobulin G isotype-switch variants of an antierythrocyte autoantibody is based on their capacity to interact in vivo with the low-affinity Fcγ receptor III. J Exp Med 191 (2000) 1293-1302
8. Fossati-Jimack L., Reininger L., Chicheportiche Y., et al. High pathogenic potential of low-affinity autoantibodies in experimental autoimmune hemolytic anemia. J Exp Med 190 (1999) 1689-1696
9. Reimer M.E., Troy G.C., and Warnick L.D. Immune-mediated hemolytic anemia: 70 cases (1988-1996). J Am Anim Hosp Assoc 35 (1999) 384-391
10. Scott-Moncrieff J.C., Treadwell N.G., McCullough S.M., and Brooks M.B. Hemostatic abnormalities in dogs with primary immune-mediated hemolytic anemia. J Am Anim Hosp Assoc 37 (2001) 220-227
11. McCullough S. Immune-mediated hemolytic anemia: understanding the nemesis. Vet Clin North Am Small Anim Pract 33 (2003) 1295-1315
12. Carr A.P., Panciera D.L., and Kidd L. Prognostic factors for mortality and thromboembolism in canine immune-mediated hemolytic anemia: a retrospective study of 72 dogs. J Vet Intern Med 16 (2002) 504-509
13. Klag A.R., Giger U., and Shofer F.S. Idiopathic immune-mediated hemolytic anemia in dogs: 42 cases (1986-1990). J Am Vet Med Assoc 202 (1993) 783-788
14. Quigley K.A., Chelack B.J., Haines D.M., and Jackson M.L. Application of a direct flow cytometric erythrocyte immunofluorescence assay in dogs with immune-mediated hemolytic anemia and comparison to the direct antiglobulin test. J Vet Diagn Invest 13 (2001) 297-300
15. Day T.K., Macintire D.K., Murtaugh R.J., and Mathews K.A. Differing opinions on treatment of immune-mediated hemolytic anemia. J Am Vet Med Assoc 218 (2001) 1414-1415
16. Mason N., Duval D., Shofer F.S., and Giger U. Cyclophosphamide exerts no beneficial effect over prednisone alone in the initial treatment of acute immune-mediated hemolytic anemia in dogs: a randomized controlled clinical trial. J Vet Intern Med 17 (2003) 206-212
17. Weinkle T.K., Center S.A., Randolph J.F., Warner K.L., Barr S.C., and Erb H.N. Evaluation of prognostic factors, survival rates, and treatment protocols for immune-mediated hemolytic anemia in dogs: 151 cases (1993-2002). J Am Vet Med Assoc 226 (2005) 1869-1880
18. Grundy S.A., and Barton C. Influence of drug treatment on survival of dogs with immune-mediated hemolytic anemia: 88 cases (1989-1999). J Am Vet Med Assoc 218 (2001) 543-546
19. Miller S.A., Hohenhaus A.E., and Hale A.S. Case-control study of blood type, breed, sex, and bacteremia in dogs with immune-mediated hemolytic anemia. J Am Vet Med Assoc 224 (2004) 232-235
20. McManus P.M., and Craig L.E. Correlation between leukocytosis and necropsy findings in dogs with immune-mediated hemolytic anemia: 34 cases (1994-1999). J Am Vet Med Assoc 218 (2001) 1308-1313
21. Klein M.K., Dow S.W., and Rosychuk R.A. Pulmonary thromboembolism associated with immune-mediated hemolytic anemia in dogs: ten cases (1982-1987). J Am Vet Med Assoc 195 (1989) 246-250
22. van Rooijen N., and van Nieuwmegen R. Elimination of phagocytic cells in the spleen after intravenous injection of liposome-encapsulated dichloromethylene diphosphonate. An enzyme-histochemical study. Cell Tissue Res 238 (1984) 355-358
23. Claassen I., Van Rooijen N., and Claassen E. A new method for removal of mononuclear phagocytes from heterogeneous cell populations in vitro, using the liposome-mediated macrophage "suicide" technique. J Immunol Methods 134 (1990) 153-161
24. Van Rooijen N., and Sanders A. Liposome mediated depletion of macrophages: mechanism of action, preparation of liposomes and applications. J Immunol Methods 174 (1994) 83-93
25. Van Rooijen N. The liposome-mediated macrophage "suicide" technique. J Immunol Methods 124 (1989) 1-6
26. Naito M., Nagai H., Kawano S., et al. Liposome-encapsulated dichloromethylene diphosphonate induces macrophage apoptosis in vivo and in vitro. J Leukoc Biol 60 (1996) 337-344
27. van Rooijen N., and Sanders A. Elimination, blocking, and activation of macrophages: three of a kind?. J Leukoc Biol 62 (1997) 702-709
28. Alves-Rosa F., Stanganelli C., Cabrera J., et al. Rapid recovery of platelet count following administration of liposome-encapsulated clodronate in a mouse model of immune thrombocytopenia. Br J Haematol 116 (2002) 357-366
29. Alves-Rosa F., Stanganelli C., Cabrera J., van Rooijen N., Palermo M.S., and Isturiz M.A. Treatment with liposome-encapsulated clodronate as a new strategic approach in the management of immune thrombocytopenic purpura in a mouse model. Blood 96 (2000) 2834-2840
30. Ceponis A., Waris E., Monkkonen J., et al. Effects of low-dose, noncytotoxic, intraarticular liposomal clodronate on development of erosions and proteoglycan loss in established antigen-induced arthritis in rabbits. Arthritis Rheum 44 (2001) 1908-1916
31. Richards P.J., Williams A.S., Goodfellow R.M., and Williams B.D. Liposomal clodronate eliminates synovial macrophages, reduces inflammation and ameliorates joint destruction in antigen-induced arthritis. Rheumatology (Oxford) 38 (1999) 818-825
32. Jordan M.B., van Rooijen N., Izui S., Kappler J., and Marrack P. Liposomal clodronate as a novel agent for treating autoimmune hemolytic anemia in a mouse model. Blood 101 (2003) 594-601
33. Buiting A.M., Zhou F., Bakker J.A., van Rooijen N., and Huang L. Biodistribution of clodronate and liposomes used in the liposome mediated macrophage "suicide" approach. J Immunol Methods 192 (1996) 55-62
34. Leenen P.J., Radosevic K., Voerman J.S., et al. Heterogeneity of mouse spleen dendritic cells: in vivo phagocytic activity, expression of macrophage markers, and subpopulation turnover. J Immunol 160 (1998) 2166-2173
35. Dow S., Elmslie R., Kurzman I., MacEwen G., Pericle F., and Liggitt D. Phase I study of liposome-DNA complexes encoding the interleukin-2 gene in dogs with osteosarcoma lung metastases. Hum Gene Ther 16 (2005) 937-946
36. Scott-Moncrieff J.C., Reagan W.J., Snyder P.W., and Glickman L.T. Intravenous administration of human immune globulin in dogs with immune-mediated hemolytic anemia. J Am Vet Med Assoc 210 (1997) 1623-1627
37. Johnson L.R., Lappin M.R., and Baker D.C. Pulmonary thromboembolism in 29 dogs: 1985-1995. J Vet Intern Med 13 (1999) 338-345
38. Kinne R.W., Schmidt-Weber C.B., Hoppe R., et al. Long-term amelioration of rat adjuvant arthritis following systemic elimination of macrophages by clodronate-containing liposomes. Arthritis Rheum 38 (1995) 1777-1790
39. van Lent P.L., van den Bersselaar L., van den Hoek A.E., et al. Reversible depletion of synovial lining cells after intra-articular treatment with liposome-encapsulated dichloromethylene diphosphonate. Rheumatol Int 13 (1993) 21-30
40. van Rooijen N., Kors N., and Kraal G. Macrophage subset repopulation in the spleen: differential kinetics after liposome-mediated elimination. J Leukoc Biol 45 (1989) 97-104
41. Barker R.N., Gruffydd-Jones T.J., Stokes C.R., and Elson C.J. Identification of autoantigens in canine autoimmune haemolytic anaemia. Clin Exp Immunol 85 (1991) 33-40
42. Barker R.N., and Elson C.J. Red blood cell glycophorins as B and T-cell antigens in canine autoimmune haemolytic anaemia. Vet Immunol Immunopathol 47 (1995) 225-238
43. Duval D., and Giger U. Vaccine-associated immune-mediated hemolytic anemia in the dog. J Vet Intern Med 10 (1996) 290-295
44. Ciavarra R.P., Taylor L., Greene A.R., et al. Impact of macrophage and dendritic cell subset elimination on antiviral immunity, viral clearance and production of type 1 interferon. Virology 342 (2005) 177-189